Curiously, a meta-analysis of ten randomized controlled trials evaluating the impact of DPP4 inhibitors on serum adiponectin of patients with type 2 diabetes confirmed significantly elevated adiponectin levels after the pharmacological inhibition of DPP4 [28]. The gene discussed is ADIPOQ; the disease is type 2 diabetes mellitus.